• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Eu­rope to buy 110k dos­es of Bavar­i­an Nordic's mon­key­pox vac­cine — as EU-li­censed vac­cine not eas­i­ly ac­ces­si­ble

3 years ago
Pharma

CVS re­sumes cov­er­age of block­buster blood thin­ner af­ter price drop fol­lows Jan­u­ary ex­clu­sion

3 years ago
Pharma

#Can­nes­Lions2022: Con­sumer health ex­ecs call on agen­cies to in­volve pa­tients in cre­ative process

3 years ago
Pharma
Marketing

#Can­nes­Lions2022 Mar­ket­ingRx roundup: Phar­ma and health fi­nal­ists packed in back of Palais base­ment dis­plays; Ryan ...

3 years ago
Marketing

No­var­tis de­tails plans to axe 8,000 staffers as Narasimhan be­gins sec­ond phase of a glob­al re­org

3 years ago
R&D

Gray­bug seeks al­ter­na­tive op­tions for eye drugs; RA-backed epilep­sy out­fit se­cures $40M Se­ries C

3 years ago
News Briefing

Jazz re­ports sur­prise PhI­II flop for cannabi­noid drug from $7.2B GW buy­out

3 years ago
R&D

#Can­nes­Lions2022: Phar­ma and health mar­keters lose spot­light at cre­ativ­i­ty ad fest, but does it mat­ter?

3 years ago
Pharma
Marketing

#Can­nes­Lions2022: Di­ver­si­ty, eq­ui­ty and in­clu­sion takes cen­ter stage as phar­ma in­dus­try is called to ac­tion

3 years ago
Pharma
Marketing

Spero’s UTI can­di­date gets the CRL ham­mer as the com­pa­ny falls in­to pen­ny stock sta­tus

3 years ago
Pharma
FDA+

A decade af­ter its first ap­proval, FDA ex­pands weight loss pil­l's la­bel for use in ado­les­cents

3 years ago
Pharma

Four months af­ter CRL due to con­t­a­m­i­nant wor­ries, Gilead re­turns to FDA for next-gen HIV drug

3 years ago
R&D
Pharma

Years af­ter link­ing arms with Bris­tol My­ers and both Mer­cks, Sutro finds its lat­est part­ner in Tokyo

3 years ago
Deals

Scoop: Roche scraps one of two schiz­o­phre­nia PhII tri­als af­ter fail­ing the pri­ma­ry end­point

3 years ago
R&D
Pharma

Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

3 years ago
Deals

Roivant chops sick­le cell gene ther­a­py, der­ma­tol­ogy drugs to fo­cus on 'high­er val­ue pro­ject­s'

3 years ago
R&D

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

3 years ago
Pharma
In Focus

Still in pre­clin­i­cal test­ing for ear gene ther­a­pies, Deci­bel touts small snap­shot of chemo-in­duced hear­ing loss drug

3 years ago
R&D

Long­time biotech leader Pearl Huang takes the reins as CEO of No­var­tis-backed up­start

3 years ago
People
Startups

Roivant un­veils lat­est spin­out as Pfiz­er en­trusts JAK1/TYK2 to Pri­o­vant

3 years ago
Startups

Alex­ion puts €65M for­ward to strength­en its po­si­tion on the Emer­ald Isle

3 years ago
Financing
Pharma

Am­gen takes next step with its Chi­na am­bi­tions, out-li­cens­ing drugs to Fo­s­un Phar­ma

3 years ago
China
Pharma

As court case looms, Bris­tol My­ers touts la­bel ex­pan­sion for Breyanzi

3 years ago
Pharma
Cell/Gene Tx

State bat­tles over mifepri­s­tone ac­cess could tie the FDA to any post-Roe cross­roads

3 years ago
FDA+
Law
First page Previous page 506507508509510511512 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times